Form 8-K - Current report:
SEC Accession No. 0001493152-22-020362
Filing Date
2022-07-26
Accepted
2022-07-26 17:15:44
Documents
23
Period of Report
2022-07-22
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 58395
2 ex4-1.htm EX-4.1 111585
3 ex4-2.htm EX-4.2 113098
4 ex4-3.htm EX-4.3 113394
5 ex4-4.htm EX-4.4 113394
6 ex4-5.htm EX-4.5 123173
7 ex5-1.htm EX-5.1 17135
8 ex10-1.htm EX-10.1 289147
9 ex10-2.htm EX-10.2 274956
10 ex10-3.htm EX-10.3 196620
11 ex10-4.htm EX-10.4 13234
12 ex99-1.htm EX-99.1 19713
  Complete submission text file 0001493152-22-020362.txt   1915695

Data Files

Seq Description Document Type Size
13 XBRL SCHEMA FILE envb-20220722.xsd EX-101.SCH 2956
14 XBRL LABEL FILE envb-20220722_lab.xml EX-101.LAB 34240
15 XBRL PRESENTATION FILE envb-20220722_pre.xml EX-101.PRE 22357
17 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3743
Mailing Address 4851 TAMIAMI TRAIL N, SUITE 200 NAPLES FL 34103
Business Address 4851 TAMIAMI TRAIL N, SUITE 200 NAPLES FL 34103 239-302-1707
Enveric Biosciences, Inc. (Filer) CIK: 0000890821 (see all company filings)

EIN.: 954484725 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38286 | Film No.: 221107871
SIC: 2834 Pharmaceutical Preparations